Hamed Cheraghmakani

Hamed Cheraghmakani

Auto-generated profile, based on publicly available information

Hamed Cheraghmakani

Neurology department, faculty of medicine, Mazandaran University of medical sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2009 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
SAShahin Akhondzadeh
Shahin Akhondzadeh
MSMehdi Shafiee Sabet
Mehdi Shafiee Sabet
MHMohammad Hossein Harirchian
Mohammad Hossein Harirchian
MTMansoreh Togha
Mansoreh Togha
HCHamed Cheraghmakani
Hamed Cheraghmakani
AVArdalan Vossoughi
Ardalan Vossoughi

13 September 2010 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SAS. Akhondzadeh
S. Akhondzadeh
MSM. Shafiee Sabet
M. Shafiee Sabet
MHM. H. Harirchian
M. H. Harirchian
MTM. Togha
M. Togha
HCH. Cheraghmakani
H. Cheraghmakani
AMA. Moradi
A. Moradi
What is known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD). Objective: The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD. Methods: Forty‐six patients with probable AD were screened for a 16‐week, double‐blind study of parallel groups of patients with mild to moderate AD. The psychometric measures, which included AD assessment scale‐cognitive subscale (ADAS‐cog), and clinical dementia rating scale‐sums of boxes, were performed to monitor the global cognitive and clinical profiles of the patients. Patients were randomly assigned to receive capsule saffron 30 mg/day (15 mg twice per day) (Group A) or capsule placebo (two capsules per day) for a 16‐week study. Results: After 16 weeks, saffron produced a significantly better outcome on cognitive function than placebo (ADAS‐cog: F = 4·12, d.f. = 1, P = 0·04; CDR: F = 4·12, d.f. = 1, P = 0·04). There were no significant differences in the two groups in terms of observed adverse events. What is new and conclusion: This double‐blind, placebo‐controlled study suggests that at least in the short‐term, saffron is both safe and effective in mild to moderate AD. Larger confirmatory randomized controlled trials are called for.

16 April 2019 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
IGIraj Golikhatir
Iraj Golikhatir
HCHamed Cheraghmakani
Hamed Cheraghmakani
FBFarzad Bozorgi
Farzad Bozorgi
FJFatemeh Jahanian
Fatemeh Jahanian
MSMohammad Sazgar
Mohammad Sazgar
SMSeyed Hosein Montazer
Seyed Hosein Montazer

2 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HCHamed Cheraghmakani
Hamed Cheraghmakani
SBSeyed Mohammad Baghbanian
Seyed Mohammad Baghbanian
RHReza HabibiSaravi
Reza HabibiSaravi
AAArash Azar
Arash Azar
FGFariba Ghasemihamedani
Fariba Ghasemihamedani
The incidence rate of MS is a valuable indicator of the recent changes in the risk of this disease, and it is widely implicated for health planning purposes. This study aims to determine the MS incidence over the past eleven years in Mazandaran province and to compare it with the other parts of Iran and the world. This retrospective study is conducted in Mazandaran province by using registered data in the files of the patients with their consent. The yearly crude incidence rates, age, and sex-specific incidence rates and directly standardized incidence rates of this population are calculated, and the temporal changes in the incidence rates are analyzed. 662 (26%) male patients with the mean (SD) age of 32.6 (9.48) and 1884 (74%) female patients with the mean (SD) age of 31.9 (9.15) are studied. The direct standardized incidence rate of MS was 3.28 in 100.000 in 2008 and reached 4.17 in 100.000 in 2018, and this increase was significant (p<0.05). Also, the yearly prevalence of MS increased from 24.4 to 72.5 in this period. The MS incidence has increased in Mazandaran. The potential role of some genetic or environmental factors needs further investigation.

1 January 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
ZBZainab Bandalizadeh
Zainab Bandalizadeh
TSTahereh Shokohi
Tahereh Shokohi
Hamid BadaliHamid Badali
Hamid Badali
MAMahdi Abastabar
Mahdi Abastabar
FBFarhang Babamahmoudi
Farhang Babamahmoudi
SSSeyedmojtaba Seyedmousavi
Seyedmojtaba Seyedmousavi
Introduction. Limited data regarding the epidemiology and susceptibility profiles of cryptococcosis are available in the Middle East. Aim. Our study aimed to evaluate the molecular diversity, mating types and antifungal susceptibility pattern of Cryptococcus species (n=14) isolated from 320 suspected patients with cryptococcosis. Methodology. The URA5 gene was subjected to restriction fragment length polymorphism and sequence analysis. In addition, in vitro antifungal susceptibility testing was performed by Clinical and Laboratory Standards Institute (CLSI) M27-A4 and M59 guidelines. Results. Overall, 14 (4.4 %) patients were confirmed as cryptococcosis. Based on molecular type, 85.7 and 14.3 % of the isolates were C. neoformans VN I and VN II, respectively. Phylogenetic analysis of URA5 gene sequences revealed clustering of VN I and VN II isolates into two distinct clades with a substantial difference within each molecular type. Voriconazole and 5-fluorocytosine, respectively, had the lowest (0.031 μg ml−1) and highest (8 µg ml−1) MICs. The epidemiological cutoff values (ECVs) for amphotericin B, fluconazole, voriconazole and 5-fluorocytosine encompassed ≥97 % of all 14 C. neoformans VN I species. However, according to the CLSI document M59, ECVs for itraconazole (7; 50 % of the isolates) and for posaconazole (1; 7.1 % of the isolate), were one log2 dilution higher than the wild type range. Combinations of amphotericin B with 5-fluorocytosine, amphotericin B with fluconazole and fluconazole with 5-fluorocytosine exhibited synergistic effects against 37, 31 and 12.5 % of the isolates, respectively. Conclusion. Our findings may significantly contribute to the development of management strategies for patients at a higher risk of cryptococcosis, particularly HIV-positive individuals.

17 June 2020 in International Journal of Neuroscience
Verified
Journal Article
Closed access
ASAthena Sharifi-Razavi
Athena Sharifi-Razavi
NKNarges Karimi
Narges Karimi
AZAshraf Zarvani
Ashraf Zarvani
HCHamed Cheraghmakani
Hamed Cheraghmakani
SBSeyed Mohammad Baghbanian
Seyed Mohammad Baghbanian
Introduction: There is limited evidence about the neurological manifestations of COVID-19 in infected patients. In this report, we describe three patients with ischemic stroke associated with COVID-19 infection. Methods: We report 3 cases of adult patients with ischemic stroke and novel coronavirus 2019 infection. Case 1 is an 88-year-old female with acute left hemiplegia and right peripheral facial paresis that she had a fever along with stroke symptoms. Case 2 is an 85-year-old female with left hemiplegia and drowsiness who had a weakness, asthenia, and dry cough 3 days before appearing stroke signs. Case 3 is a 55-year-old male with acute Brocaʼs aphasia and right hemiplegia who experience fever and respiratory problems 3 days after admission. Results: The clinical symptoms of infected patients with COVID-19 have been associated with severe symptoms of ischemic stroke. Two patients were admitted to the ICU. RT-PCR of the oropharyngeal sample was positive in three cases. All patients had the involvement of large cerebral arteries. Conclusion: The mechanism by which COVID-19 causes ischemic stroke is unknown but it is likely by production inflammatory cytokines or direct infection of cerebral arteries. Therefore, regarding the current situation of the COVID-19 pandemic, it is indispensable that the possible diagnosis of COVID-19 vasculopathy is considered in all ischemic strokes of unclear etiology.